OptimizeRx Corp $OPRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Services-Business Services, NEC
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 18,835,951 [10-Q 2026-08-13]
What the company doesAI summary of filing
OptimizeRx develops digital healthcare marketing technology for life sciences companies to engage healthcare providers and patients. The company offers AI-enabled platforms and solutions including its Dynamic Audience Activation Platform (DAAP) for targeting healthcare providers, Micro-Neighborhood® Targeting (MNT) for direct-to-consumer marketing using de-identified claims data, audience profiling tools, media execution services, pharmacy alerts, and financial messaging for copay offers. OptimizeRx is revenue-generating, serving over 100 pharmaceutical manufacturers and making money by delivering targeted marketing messages and data analytics services through its proprietary omnichannel network that reaches over two million U.S. healthcare providers. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $40.35M | −$1.20M | $8.14M | $24.10M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $109.43M | $5.13M | $18.71M | $23.36M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $92.13M | −$20.11M | $4.89M | $13.38M | [10-K 2026-03-12] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 18,420,906 | [10-Q 2024-11-14] |
| 2025-03-11 | 18,490,385 | [10-K 2025-03-20] |
| 2025-05-06 | 18,495,111 | [10-Q 2025-05-13] |
| 2025-07-25 | 18,565,033 | [10-Q 2025-08-08] |
| 2025-10-24 | 18,640,652 | [10-Q 2025-11-07] |
| 2026-02-26 | 18,762,203 | [10-K 2026-03-12] |
| 2026-04-29 | 18,765,075 | [10-Q 2026-05-13] |
| 2026-07-30 | 18,835,951 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2025-03-28; declared effective 2025-04-07 [S-3 2025-03-28]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | D'Silva Andrew J. | other | 414 | $8.39 | [4 2026-10-02] |
| 2026-09-01 | D'Silva Andrew J. | other | 1,432 | $7.86 | [4 2026-09-02] |
| 2026-08-21 | Merrell Brendan W. | other | 1,020 | $7.71 | [4 2026-08-24] |
| 2026-08-21 | Silvestro Stephen L | other | 1,737 | $7.71 | [4 2026-08-24] |
| 2026-08-20 | Silvestro Stephen L | grant | 79,200 | — | [4 2026-08-24] |
| 2026-08-20 | D'Silva Andrew J. | grant | 57,600 | — | [4 2026-08-24] |
| 2026-08-20 | Merrell Brendan W. | grant | 57,600 | — | [4 2026-08-24] |
| 2026-08-20 | Odence-Ford Marion | grant | 57,600 | — | [4 2026-08-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations; Director or officer change; Regulation FD disclosure |
| 2026-07-29 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-22 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-12 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-05 | 8-K | Director or officer change |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Material agreement entered; Material agreement terminated; Results of operations |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-09 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-03-30 | 8-K | Auditor change |
Alerts for $OPRX
Email me when OptimizeRx Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.